<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; therapy</title>
	<atom:link href="http://www.tapanray.in/tag/therapy/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Collaboration For Sustainable Excellence – The Name of The Game in The New Normal</title>
		<link>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal</link>
		<comments>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 May 2023 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[digital tools]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[new therapeutics]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10785</guid>
		<description><![CDATA[The union minister of health and family welfare of India recently invited Japanese companies to collaborate with Indian companies on research and innovation in emerging therapies, like precision medicine, cell and gene therapy, biological products, and on the utilization of &#8230; <a href="http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Integrity Issue Haunts Again With Covid Vaccine?</title>
		<link>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-integrity-issue-haunts-again-with-covid-vaccine</link>
		<comments>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/#comments</comments>
		<pubDate>Mon, 29 Mar 2021 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[ghosts]]></category>
		<category><![CDATA[haunts. AstraZeneca]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10454</guid>
		<description><![CDATA[On March 22, 2021, by a media release, AstraZeneca announced that its ‘US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% in preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.’ Quite unexpectedly, on March &#8230; <a href="http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Still Evolving: Pharma’s New Pathway For Digital And F2F Customer Engagement</title>
		<link>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement</link>
		<comments>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/#comments</comments>
		<pubDate>Mon, 15 Feb 2021 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Customer-Engagement]]></category>
		<category><![CDATA[Digital F2F]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Evolving. Pharma]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[inbound]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interactions]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outbound]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[preference]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[uncertain]]></category>
		<category><![CDATA[visits]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10415</guid>
		<description><![CDATA[Last year &#8211; probably left with no better choice &#8211; the pharma industry, in general, had to take an unprecedented interest in digitalization of business processes. It happened faster than ever, especially in the marketing domain, along with a few &#8230; <a href="http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid-19: Perils Of Haste In Scientific Decision-Making Process</title>
		<link>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-19-perils-of-haste-in-scientific-decision-making-process</link>
		<comments>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/#comments</comments>
		<pubDate>Mon, 31 Aug 2020 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[Chlioroquine]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[haste]]></category>
		<category><![CDATA[hydroxychloroquine]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[perils]]></category>
		<category><![CDATA[plasma]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scientific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[WIP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10243</guid>
		<description><![CDATA[Multifaceted threats posed by Coronavirus to the humanity, are getting increasingly complex, every day. Currently, Covid-19 cases in India are ‘the highest that any country has ever recorded on a single day since the start of the outbreak.’ Alongside, the hopes of billions &#8230; <a href="http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Any Threat To Current Commercial Model Of ‘Gene Therapy’?</title>
		<link>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=any-threat-to-current-commercial-model-of-gene-therapy</link>
		<comments>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/#comments</comments>
		<pubDate>Mon, 30 Dec 2019 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CAR-T]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genetic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9833</guid>
		<description><![CDATA[Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020 &#160; One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers &#8230; <a href="http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On The Flip Side of Pharma Industry: A Saga of Perennial Contradictions</title>
		<link>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions</link>
		<comments>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/#comments</comments>
		<pubDate>Mon, 09 Dec 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEOs]]></category>
		<category><![CDATA[contradiction]]></category>
		<category><![CDATA[contradictions]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[flip]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[perennial]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[side]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vice versa]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9804</guid>
		<description><![CDATA[Awesome contribution in the battle against multiple diseases, is obviously the primary facet of the pharma industry. However, on its flip side, one would witness a saga of numerous contradictions. Some of these exist perennially in well-protected opaque cocoons, regardless &#8230; <a href="http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dynamics of Cancer Therapy Segment Remain Enigmatic</title>
		<link>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dynamics-of-cancer-therapy-segment-remain-enigmatic</link>
		<comments>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/#comments</comments>
		<pubDate>Mon, 14 Oct 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Assistance]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[enigma]]></category>
		<category><![CDATA[enigmatic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[PAP]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[program]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UICC]]></category>
		<category><![CDATA[Union for International Cancer Control]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9745</guid>
		<description><![CDATA[Currently, cancer is likely to occupy the center stage on any discussion related to the fastest growing therapy segments in the pharma or biotech industries. There are several reasons behind such probability, some of which include: Cancer is not only &#8230; <a href="http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A New Facet of ‘Data Integrity’ With Novel Therapy… And Much Beyond</title>
		<link>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond</link>
		<comments>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/#comments</comments>
		<pubDate>Mon, 30 Sep 2019 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AveXis]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[cherry-picking]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9728</guid>
		<description><![CDATA[The peril of breach of data integrity involving a top Indian pharma player, jolted many, probably for the first time, on September 17, 2008. On that day, the USFDA, reportedly, issued two ‘Warning Letters’ and an ‘Import Alert’. These were related to &#8230; <a href="http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gene Therapy Price: Commercial Viability And Moral Dilemma</title>
		<link>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gene-therapy-price-commercial-viability-and-moral-dilemma</link>
		<comments>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/#comments</comments>
		<pubDate>Mon, 17 Jun 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercially]]></category>
		<category><![CDATA[dilemma]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[moral]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Spinraza]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[viability.]]></category>
		<category><![CDATA[viable]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9586</guid>
		<description><![CDATA[On May 24, 2019, Novartis announced the US-FDA approval of ‘the first and only gene therapy’ – Zolgensma, for a type of Spinal Muscular Atrophy (SMA), a lifesaving treatment for infants of less than 2 years of age. This unique drug halts disease progression &#8230; <a href="http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Game is Changing: Ensure Better Treatment Outcomes: Leverage Technology</title>
		<link>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology</link>
		<comments>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/#comments</comments>
		<pubDate>Mon, 03 Jun 2019 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[augmentation]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Digihaler]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[non-drug]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[ProAir]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replacement]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[types]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9570</guid>
		<description><![CDATA[Today, several pharma players, mostly ‘encouraged’ by many non-pharma tech companies, are trying to gain, at least, a toehold in the digital health care space. It is visible even within the generic drug industry. Such initiatives, as they gain a &#8230; <a href="http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
